Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Jordan Lye/Moment via Getty Images Topline Summary Atara Biotherapeutics (NASDAQ:ATRA) is a commercial-stage biotech focused on the development and commercialization of cell therapies for patients with Epstein-Barr virus infection associated diseases and cancer. While they had a prominent trial failure late last year, they are generating revenues and improving their cash runway all the time. I'm rating this a buy because there is a lot of potential for valuation appreciation if they can remove some of t ...